Generate Biomedicines and Zealand Pharma Collaborate to Develop Obesity Treatments Using AI
Generate Biomedicines (GENB) has partnered with Zealand Pharma (ZLDPF) to develop novel protein therapeutics for obesity and metabolic diseases using an advanced artificial intelligence platform. The collaboration leverages Generate's proprietary platform, which combines generative AI with high-throughput experimental validation to accelerate drug discovery. This partnership aims to address significant unmet medical needs in the treatment of metabolic disorders by leveraging cutting-edge technology to identify promising therapeutic candidates more efficiently than traditional methods. Zealand will contribute its expertise in peptide-based therapeutics and clinical development experience, while Generate provides its AI-driven platform for protein design and validation. The collaboration highlights a growing trend among biotech firms to integrate artificial intelligence into drug discovery processes, potentially reducing time-to-market and increasing the success rate of new therapies.
Tickers: $GENB
Topics: AI drug development biotechnology metabolic diseases obesity therapeutics